TREM1 and kidney disorder: To test whether this translated to in vivo kidney disease, we induced two different models of kidney injury in mice, UUO and U-IRI, which are characterized by progressive interstitial inflammation and fibrosis [35], and administered TREM1-Fc daily by i.p. injections at a dose of 40 μg/mouse, to give a predicted ECF volume concentration of 4 μg/ml or control human IgG1 (Fig. 3A).